Vevorisertib

ARQ 751 · ArQule, Inc. (a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Vevorisertib, covering 2022-06-15 to 2022-06-15. Get the full timeline:

Most recent: Clinical Trial Update: Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) [Phase 1]

See pricing